Matches in Wikidata for { <http://www.wikidata.org/entity/Q104269351> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- Q104269351 description "2020 ވަނަ އަހަރުގެ ޑިސެމްބަރުމަހުގެ 7ވަނަ ދުވަހު ޝާއިރުކުރެވުނު ސައިންޓިފިކް ލިޔުމެއް" @default.
- Q104269351 description "article scientifique publié en 2020" @default.
- Q104269351 description "artículu científicu espublizáu n'avientu de 2020" @default.
- Q104269351 description "scientific article published on 07 December 2020" @default.
- Q104269351 description "wetenschappelijk artikel" @default.
- Q104269351 description "наукова стаття, опублікована 7 грудня 2020" @default.
- Q104269351 name "Validation of highly selective sphingosine kinase 2 inhibitors SLM6031434 and HWG-35D as effective anti-fibrotic treatment options in a mouse model of tubulointerstitial fibrosis" @default.
- Q104269351 name "Validation of highly selective sphingosine kinase 2 inhibitors SLM6031434 and HWG-35D as effective anti-fibrotic treatment options in a mouse model of tubulointerstitial fibrosis" @default.
- Q104269351 name "Validation of highly selective sphingosine kinase 2 inhibitors SLM6031434 and HWG-35D as effective anti-fibrotic treatment options in a mouse model of tubulointerstitial fibrosis" @default.
- Q104269351 type Item @default.
- Q104269351 label "Validation of highly selective sphingosine kinase 2 inhibitors SLM6031434 and HWG-35D as effective anti-fibrotic treatment options in a mouse model of tubulointerstitial fibrosis" @default.
- Q104269351 label "Validation of highly selective sphingosine kinase 2 inhibitors SLM6031434 and HWG-35D as effective anti-fibrotic treatment options in a mouse model of tubulointerstitial fibrosis" @default.
- Q104269351 label "Validation of highly selective sphingosine kinase 2 inhibitors SLM6031434 and HWG-35D as effective anti-fibrotic treatment options in a mouse model of tubulointerstitial fibrosis" @default.
- Q104269351 prefLabel "Validation of highly selective sphingosine kinase 2 inhibitors SLM6031434 and HWG-35D as effective anti-fibrotic treatment options in a mouse model of tubulointerstitial fibrosis" @default.
- Q104269351 prefLabel "Validation of highly selective sphingosine kinase 2 inhibitors SLM6031434 and HWG-35D as effective anti-fibrotic treatment options in a mouse model of tubulointerstitial fibrosis" @default.
- Q104269351 prefLabel "Validation of highly selective sphingosine kinase 2 inhibitors SLM6031434 and HWG-35D as effective anti-fibrotic treatment options in a mouse model of tubulointerstitial fibrosis" @default.
- Q104269351 P1433 Q104269351-A8DB2581-E517-4634-9FBD-EFEC7E414823 @default.
- Q104269351 P1476 Q104269351-151ADBA0-99A0-4F88-A8FC-F974D8F324C2 @default.
- Q104269351 P2093 Q104269351-00868006-2661-4517-B88B-FCBBF0CC55B8 @default.
- Q104269351 P2093 Q104269351-0969D5AE-9321-424C-AE91-B34609078688 @default.
- Q104269351 P2093 Q104269351-20B12977-B94F-408C-9246-188F65740B33 @default.
- Q104269351 P2093 Q104269351-497CFBDA-30BC-4EFB-BE9D-B151E0F6970D @default.
- Q104269351 P2093 Q104269351-4D880667-6B47-470F-9BA7-683709340EDA @default.
- Q104269351 P2093 Q104269351-779F3C8B-50F5-46BE-BE5A-8C645C1FE7F4 @default.
- Q104269351 P2093 Q104269351-A8934FC3-D9C7-4749-B7FA-66EAD5F78FBA @default.
- Q104269351 P2093 Q104269351-AED0D7D3-7B48-4EEA-851B-A9061D6C610C @default.
- Q104269351 P2093 Q104269351-D494AEF9-EF31-4A0A-AAED-FA4899FD3028 @default.
- Q104269351 P2093 Q104269351-EC2B239A-0414-4268-8204-26F580693133 @default.
- Q104269351 P2860 Q104269351-C960FF1C-848E-49AE-BB0A-1232A3A80059 @default.
- Q104269351 P304 Q104269351-E91BC012-EB3A-4DB6-B9EE-1AE1A833F8A0 @default.
- Q104269351 P31 Q104269351-D82A6A82-A617-441E-B4BE-252BC7FD5311 @default.
- Q104269351 P356 Q104269351-6DDFB577-8909-48A7-B7B7-8DCBC1902197 @default.
- Q104269351 P50 Q104269351-EE5075C0-F54E-41E0-8AC1-5F2D35F17515 @default.
- Q104269351 P577 Q104269351-47542887-8D6B-43D7-9539-9EE6DE46A57F @default.
- Q104269351 P698 Q104269351-D9D61D45-A401-4F8A-8740-2004D6DC6944 @default.
- Q104269351 P356 J.CELLSIG.2020.109881 @default.
- Q104269351 P698 33301900 @default.
- Q104269351 P1433 Q1524097 @default.
- Q104269351 P1476 "Validation of highly selective sphingosine kinase 2 inhibitors SLM6031434 and HWG-35D as effective anti-fibrotic treatment options in a mouse model of tubulointerstitial fibrosis" @default.
- Q104269351 P2093 "Andrea Huwiler" @default.
- Q104269351 P2093 "David R Adams" @default.
- Q104269351 P2093 "Gerd Geisslinger" @default.
- Q104269351 P2093 "Josef Pfeilschifter" @default.
- Q104269351 P2093 "Nigel Pyne" @default.
- Q104269351 P2093 "Redona Hafizi" @default.
- Q104269351 P2093 "Sandra Beyer" @default.
- Q104269351 P2093 "Sandra Trautmann" @default.
- Q104269351 P2093 "Stephanie Schwalm" @default.
- Q104269351 P2093 "Susan Pyne" @default.
- Q104269351 P2860 Q37688040 @default.
- Q104269351 P304 "109881" @default.
- Q104269351 P31 Q13442814 @default.
- Q104269351 P356 "10.1016/J.CELLSIG.2020.109881" @default.
- Q104269351 P50 Q55296508 @default.
- Q104269351 P577 "2020-12-07T00:00:00Z" @default.
- Q104269351 P698 "33301900" @default.